Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 4;12(13):e029593.
doi: 10.1161/JAHA.122.029593. Epub 2023 Jun 22.

Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT

Nishant P Shah  1   2 , Darren K McGuire  3   4 , Christopher P Cannon  5 , Robert P Giugliano  5 , Yuliya Lokhnygina  1   2 , Courtney B Page  2 , Andrew M Tershakovec  6 , Eugene Braunwald  5 , Michael A Blazing  1   2
Affiliations

Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT

Nishant P Shah et al. J Am Heart Assoc. .
No abstract available

Keywords: LDL‐C; diabetes; ezetimibe; lipids; prevention.

PubMed Disclaimer

References

    1. Preiss D. Risk of incident diabetes with intensive‐dose compared with moderate‐dose statin therapy. JAMA. 2011;305:2556–2564. doi: 10.1001/jama.2011.860 - DOI - PubMed
    1. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397. doi: 10.1056/NEJMoa1410489 - DOI - PubMed
    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, et al. Diagnosis and management of the metabolic syndrome. Circulation. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404 - DOI - PubMed
    1. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, Heo JH, Rha SW, Cho YH, Lee SJ, et al. Long‐term efficacy and safety of moderate‐intensity statin with ezetimibe combination therapy versus high‐intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open‐label, non‐inferiority trial. Lancet. 2022;400:380–390. doi: 10.1016/S0140-6736(22)00916-3 - DOI - PubMed
    1. Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni‐Berthold I, Lewis BS, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new‐onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–950. doi: 10.1016/S2213-8587(17)30313-3 - DOI - PubMed

Publication types

MeSH terms

Substances